Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence.
D. F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; GlaxoSmithKline
Honoraria - Lilly
Research Funding - Amgen; Genentech; Genta
P. Sharma
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
R. B. Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
A. Sandler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
S. P. Lerner
Consultant or Advisory Role - Dendreon